Last reviewed · How we verify
Placebo (for metformin)
A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and physiological expectation rather than direct drug action.
A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and physiological expectation rather than direct drug action. Used for Control comparator in metformin clinical trial.
At a glance
| Generic name | Placebo (for metformin) |
|---|---|
| Also known as | placebo |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to measure the effect of patient expectation and the natural disease course independent of active drug treatment. In this case, it serves as a comparator to metformin in a clinical study conducted at Seoul National University Hospital. Any observed benefits result from placebo effect, regression to the mean, or natural disease progression rather than from the substance itself.
Approved indications
- Control comparator in metformin clinical trial
Common side effects
Key clinical trials
- Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2)
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients (PHASE3)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (PHASE2)
- A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PHASE3)
- Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for metformin) CI brief — competitive landscape report
- Placebo (for metformin) updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI